头孢洛扎-他唑巴坦与头孢他啶-阿维巴坦治疗耐药铜绿假单胞菌感染的系统综述与荟萃分析
该系统综述与荟萃分析比较头孢洛扎-他唑巴坦与头孢他啶-阿维巴坦治疗多重耐药/难治性铜绿假单胞菌感染的效果。纳入6项观察性研究共1161例患者,经混杂因素调整后,头孢洛扎-他唑巴坦的临床治愈率更高,但微生物学失败、90天耐药发生及30天死亡率无差异。
要点
- 在MDR/DTR铜绿假单胞菌感染中,头孢洛扎-他唑巴坦的临床治愈率高于头孢他啶-阿维巴坦。
- 两药在微生物学失败、90天耐药发生和30天死亡率方面未见差异。
- 结论基于观察性研究的荟萃分析,需结合临床实际个体化选择。
核心结论
- 经混杂因素调整后,头孢洛扎-他唑巴坦在治疗MDR/DTR铜绿假单胞菌感染时可能较头孢他啶-阿维巴坦提供更高的临床治愈率。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed-MEDLINE和Scopus数据库(截至2025年11月18日),纳入6项观察性研究,共1161例患者(头孢洛扎-他唑巴坦组644例,头孢他啶-阿维巴坦组517例)。
主要发现
- 临床治愈率:头孢洛扎-他唑巴坦优于头孢他啶-阿维巴坦(n=4;OR 1.82,95%CI 1.10-2.99;I²=25.3%)。
关键数值与推荐
- 主要结局为临床治愈,次要结局包括90天耐药发生、微生物学失败和30天死亡率。
- 合并效应量采用随机效应模型逆方差法计算的调整后比值比(OR)。
临床怎么用
- 对于MDR/DTR铜绿假单胞菌感染,在考虑临床治愈率时可优先考虑头孢洛扎-他唑巴坦,但需结合药敏、耐受性和可及性个体化决策。
局限性
- 纳入研究均为观察性研究,存在残余混杂可能;部分结局分析的研究数量较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ceftolozane-tazobactam and ceftazidime-avibactam are considered first-line treatment for multidrug-resistant (MDR) and/or difficult-to-treat resistant (DTR) Pseudomonas aeruginosa infections. Conflicting results in terms of clinical outcome and resistance development emerged from real-world comparative studies. We performed a systematic review with meta-analysis to compare ceftolozane-tazobactam and ceftazidime-avibactam in the treatment of MDR/DTR P. aeruginosa infections. METHODS: Two authors independently searched PubMed-MEDLINE and Scopus databases from inception to 18 November 2025 to retrieve studies comparing ceftolozane-tazobactam versus ceftazidime-avibactam in the management of MDR/DTR P. aeruginosa infections. Clinical cure was set as the primary outcome, whereas 90-day resistance development, microbiological failure, and the 30-day mortality rate were set as the secondary outcomes. Meta-analysis was performed by pooling the odds ratios (ORs) retrieved from studies providing adjustment for confounders by means of a random-effects model with the inverse variance method. The risk of bias in the included studies was independently assessed using the RoB 2.0 and the ROBINS-I tools. RESULTS: Among a total of 1193 articles screened, 6 observational studies were retrieved and included (n = 1161; 644 receiving ceftolozane-tazobactam vs 517 receiving ceftazidime-avibactam). Ceftolozane-tazobactam showed a higher clinical cure rate than ceftazidime-avibactam (n = 4; OR, 1.82 [95% confidence interval, 1.10-2.99]; I2 = 25.3%). No difference emerged in terms of microbiological failure (n = 2; OR, 0.66 [95% confidence interval, .36-1.19]; I2 = 21.9%), 90-day resistance development (n = 3; OR, 1.11 [.51-2.42]; I2 = 50.0%), or 30-day mortality rate (n = 4; OR, 1.00 [.89-1.12]; I2 = 0.0%). CONCLUSIONS: Our meta-analysis showed that, after appropriate adjustment for confounders, ceftolozane-tazobactam could grant a higher clinical cure rate than ceftazidime-avibactam in the treatment of MDR/DTR P. aeruginosa infections.
引用
- Gatti M, De Paola R, Giorgi B, et al. Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2026. PMID: 41844194. doi:10.1093/cid/ciag194
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。